Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways.
Tassi E
Clin Cancer Res. 2012 May 2;18(12):3316-27. doi: 10.1158/1078-0432.CCR-11-2232
Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target.
Zappasodi R
Blood. 2011 Aug 22;118(16):4421-30. doi: 10.1182/blood-2011-06-364570
Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia.
Guidetti A
Cancer. 2011 May 12;117(22):5074-84. doi: 10.1002/cncr.26182
Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis.
Servida F
Invest New Drugs. 2010 Jul 8;29(6):1264-75. doi: 10.1007/s10637-010-9475-6
Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death.
Zappasodi R
Cancer Res. 2010 Sep 30;70(22):9062-72. doi: 10.1158/0008-5472.CAN-10-1825
Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience.
Viviani S
Leuk Lymphoma. 51(7):1251-9. doi: 10.3109/10428194.2010.486090
Human CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand target both tumor cells and tumor vasculature.
Lavazza C
Blood. 2010 Jan 14;115(11):2231-40. doi: 10.1182/blood-2009-08-239632
Radioimmunotherapy and secondary leukemia: a case report.
Magni M
Leuk Res. 2009 May 15;34(1):e1-4. doi: 10.1016/j.leukres.2009.04.028
Efficacy and safety of high-dose chemotherapy with in vivo purged auto-SCT in relapsed follicular lymphoma: long-term follow-up.
Magni M
Bone Marrow Transplant. 2009 Oct 12;45(6):1119-20. doi: 10.1038/bmt.2009.294
Comparative assessment of telomere length before and after hematopoietic SCT: role of grafted cells in determining post-transplant telomere status.
Ruella M
Bone Marrow Transplant. 2009 Oct 19;45(3):505-12. doi: 10.1038/bmt.2009.297